Iroko Pharmaceuticals
Posted on: November 21, 2013
By: wordpress
With: Comments Off on Iroko Pharmaceuticals
Exclusive financial advisor to Iroko to enter into a $75m debt facility agreement to support general business operations and the launch of Zorvolex (diclofenac)